Login / Signup

Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders.

Andrea CalcagnoIvano Dal ConteDario CattaneoRoberto TestiMassimiliano MistrangeloCristina GervasoniAmedeo de NicolòStefano BonoraAntonio D'AvolioGiovanni Di Perri
Published in: Antimicrobial agents and chemotherapy (2020)
Four pre-exposure prophylaxis (PrEP) users with gastro-intestinal disorders (sleeve gastrectomy, terminal ileitis, celiac disease or chronic diarrhea) and receiving oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) were included. Despite a self-reported high adherence, trough plasma tenofovir concentrations (after a supervised intake) were significantly lower than those observed in PrEP recipients without gastrointestinal disorders [21 (±9.1) vs. 138 (±85) ng/mL]. PrEP users with gastrointestinal disorders may need increased TDF doses or alternative prophylactic measures.
Keyphrases